The “Hepatocellular Carcinoma – Opportunity Analysis and Forecasts to 2029” report has been added to ResearchAndMarkets.com’s offering.
The pipeline drugs in development for HCC are mostly already approved for other indications and HCC represents a growth strategy for the brands.
There are currently nine pipeline products in Phase III clinical trial; additionally, seven marketed agents are in clinical trials to expand their labels in new lines of therapy and new combinations within HCC.
The most common MOAs under investigation for HCC include tyrosine kinase inhibitors (TKI) and immuno-oncology (IO) agents (programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors, and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitors). In addition to the active late-stage pipeline, there are a large number of ongoing Phase I and II trials.
Hepatocellular carcinoma (HCC) is the most frequent type of primary malignancy of the liver. The prognosis of HCC is dependent on the stage of the disease at diagnosis.
However, even with treatments such as surgical resection, liver transplantation, and ablative therapies, which are only suitable for early-stage HCC patients, the majority of patients are likely to progress onto the advanced stages of the disease.
Until the entry of Roche’s combination therapy of Avastin + Tecentriq in May 2020, Bayer’s multikinase inhibitor commanded the largest first-line and second-line patient share in the HCC market.
This led to a shift in multikinase inhibitor monotherapy as standard of care (SOC) and initiated a new strategy in the HCC market whereby combinations are now the predominant therapeutic option under development.
Key Highlights
-
Upon approval of Avastin + Tecentriq by the FDA, in May 2020, the combination replaced the SoC in first-line advanced HCC, shifting Nexavar and Lenvima to second-line treatment options.
-
The greatest drivers of growth in the global HCC market include the launch of new pipeline therapies, combinations of therapies with different MOAs, label expansion from other oncology indications to HCC, and label expansion into earlier lines of therapy, in addition to an increase in diagnosed incident cases in many 8MM countries.
-
The main barrier to growth in the HCC market is patent expiration of key biologic brands with subsequent biosimilar launch.
-
The most important unmet needs in the HCC market are better HCC surveillance and prophylactic treatments, curative therapies in early-stage HCC, improved survival for intermediate-stage HCC, data on sequencing of treatments, prognostic biomarkers, treatments for patients with impaired liver function.
Key Topics Covered:
1 Tables & Figures
2 Hepatocellular Carcinoma: Executive Summary
2.1 Global HCC Market Expected to Grow at 17.7% CAGR to $5.3B During 2019-2029
2.2 Competitive Market with New Strategies to Gain Patient Share in the HCC Market
2.3 High Level of Unmet Needs Leaves Room for Further Research
2.4 Opportunity for Pipeline Agents with First-in-Class Approvals
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology
4.1.1 HBV and HCV Infection
4.1.2 Alcohol
4.1.3 NAFLD
4.2 Pathophysiology
4.2.1 MAPK Pathway
4.2.2 PI3K/Akt Pathway
4.2.3 Wnt/catenin Pathway
4.2.4 JAK/STAT Pathway
4.3 Surveillance of HCC
4.4 Biomarkers
4.5 Clinical Staging and Treatment Guidelines
4.6 Prognosis and Progression
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for HCC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 COVID-19 Impact
5.6.3 Limitations of Analysis
5.6.4 Strengths of Analysis
6 Current Treatment Options
6.1 Overview
6.2 Curative Therapy
6.2.1 Surgical Approaches: Transplant and Resection
6.2.2 Local Ablative Therapies
6.3 Non-curative/Palliative Therapy
6.3.1 Transarterial Regional Therapies
6.3.2 Systemic Therapy
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Better HCC Surveillance and Prophylactic Treatments
7.3 More Effective Treatments
7.3.1 Curative Therapies in Early-Stage HCC
7.3.2 Improved Survival for Intermediate-Stage HCC
7.4 Data on Sequencing of Treatments
7.5 Prognostic Biomarkers
7.6 Treatments for Patients with Impaired Liver Function
8 R&D Strategies
8.1 Overview
8.1.1 Combination Therapies with Different MOAs
8.1.2 Label Expansion from Other Oncology Indications to HCC as Part of Lifecycle Management
8.1.3 Label Expansion into Earlier Lines of Therapy
8.2 Clinical Trials Design
8.2.1 Clinical Trial Design Flaws
8.2.2 Appropriate Active Comparator in HCC Clinical Trials
9 Pipeline Assessment
9.1 Overview
9.1.1 Adjuvant Treatment
9.1.2 Intermediate HCC
9.1.3 Advanced HCC
9.2 Innovative Early-Stage Approaches
9.3 Other Drugs in Development
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.1.1 Adjuvant Treatment
10.1.2 Intermediate HCC
10.1.3 Advanced HCC
10.2 Commercial Benchmark of Key Pipeline Drugs
10.2.1 Adjuvant Treatment
10.2.2 Intermediate HCC
10.2.3 Advanced HCC
10.3 Competitive Assessment
10.3.1 Adjuvant Treatment
10.3.2 Intermediate HCC
10.3.3 Advanced HCC
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 China
11 Appendix
Companies Mentioned
-
AstraZeneca
-
Bayer
-
BMS
-
Onyx Pharmaceuticals
-
Eisai
-
Exelixis
-
Roche/Genentech
-
Merck & Co.
-
Novartis
-
Ono
-
ImClone Systems
-
Suzhou Zelgen Biopharmaceutical
-
Jiangsu Hengrui Medicine
-
BeiGene Ltd
-
CStone Pharmaceuticals Co
-
Innovent Biologics
-
Shanghai Junshi Bioscience
For more information about this report visit https://www.researchandmarkets.com/r/1iawba
View source version on businesswire.com: https://www.businesswire.com/news/home/20210412005686/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
